Effect of supplementation in treatment of polycystic ovary syndrome

Phase 3

Conditions: Polycystic ovary syndrome.
Polycystic ovarian syndrome
E28.2

Registration Number: IRCT201502055623N34

Lead Sponsor: Arak University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: Female

Target Recruitment: 64

Inclusion Criteria

Women aged 18-40 years diagnosed with PCOS

Exclusion Criteria

Women with hyperprolactinemia
Diabetes mellitus
Thyroid disease
Adrenal hyperplasia
Consumed effective drugs on hormonal profile
Ovulation induction agents
Anti-obesity and antidepressants in the last 3 months before enrollment

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Insulin resistance. Timepoint: At the beginning of the study and after 8 weeks of the intervention. Method of measurement: Calculation with HOMA formula.

Secondary Outcome Measures

Name	Time	Method
Insulin. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: ELISA kit.;Cholesterol. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;VLDL. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;LDL. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;FPG. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.